R eliable sensing and detection of ventricular fibrillation (VF) and rapid, life-threatening ventricular tachycardia (VT) was a challenge for early implantable cardioverter-defibrillators (ICDs). Manufacturers responded with improved technology; in this century, reports of failure to treat life-threatening VT or VF have been rare and limited to one [1] [2] [3] [4] or a few patients. 5, 6 In the last decade, investigators focused on preventing unnecessary ICD therapies by strategic programming, including faster detection rates, longer detection times, discriminators for supraventricular tachycardia (SVT), and enhancements to prevent oversensing. 7 Clinical studies [8] [9] [10] [11] [12] [13] report that strategic programming reduces unnecessary therapies without withholding therapy for life-threatening VT/VF. Each study used ICDs from a single manufacturer. Programmed parameters were strictly controlled within each study, but they varied among studies. The 2015 HRS/EHRA/ APHRS/SOLAECE Consensus Statement on Optimal ICD Programming and Testing 7 (Consensus Statement) provides generic programming recommendations. For some ICDs, these recommendations are necessarily extrapolated from evidence obtained using another manufacturer's ICDs with different sensing and detection features. In a series of cases, we sought to determine the reasons that contemporary ICD systems failed to deliver therapy for life-threatening VT/VF in the era of strategic programming.
METHODS

Patient Selection
The 10 patients were ambulatory, expected to live >1 year, and did not have an acute illness. They met these criteria: (1) a shock for life-threatening VT/VF was either not delivered or delayed significantly, resulting in death or a major adverse event. For simplicity, we refer to failure to deliver timely therapy. ( 2) The ICD system functioned normally.
(3) VT/VF detection and therapies were programmed ON. (4) The amplitude of sinus-rhythm R waves exceeded 5 mV at implant and follow-up. Index events occurred from April 2015 to January 2017. No patient who met the inclusion criteria was excluded. Patients 1 to 8 were programmed and followed at 1 of the 4 participating
WHAT IS KNOWN
• In clinical trials, manufacturer-specific, strategic programming of implantable cardioverterdefibrillators (ICDs) reduces unnecessary therapy but permits therapy for ventricular tachycardia/ fibrillation. • Present guidelines provide generic programming recommendations. For some ICDs, these recommendations are extrapolated from evidence obtained using other manufacturer's ICDs with different sensing and detection features.
WHAT THE STUDY ADDS
• No patient with manufacturer-specific, programming validated in a clinical trial failed to receive an initial, timely shock for ventricular fibrillation. • Most patients who did not receive timely ventricular fibrillation shocks had ICDs programmed consistent with guidelines extrapolated from evidence obtained using another manufacturer's ICDs with different sensing and detection features. • More data are needed to assess both the benefits and risks of applying generic programming recommendations to specific ICDs in which these recommendations have not been validated clinically.
institutions; patients 9 and 10 were programmed and followed at a community hospital; they were brought to a participating institution for tertiary care during their index events. To estimate completeness of inclusion, we reviewed all deaths and resuscitated cardiac arrests in ICD patients during the study period at the 2 institutions that tracked these data. This study was approved by the Institutional Committees on Human Research at the authors' institutions.
ICD Programming: Compliance With Recommendations
The Consensus Statement 7 provides 32 generic recommendations for tachycardia detection. Its online Appendix B provides programming examples that may be considered manufacturer-preferred values. We reviewed programming for compliance or noncompliance with both generic and manufacturer-preferred recommendations that influence detection of VT/VF, including rate threshold and SVT discriminators. Programmed sensitivity and duration also influence detection; but, in all study patients, sensitivity was nominal and noncompliant durations were shorter than recommended, increasing rather than decreasing the likelihood of VT/VF detection.
The Consensus Statement recommends programming the slowest rate threshold between 185 and 200 beats per minute for primary prevention and ≤200 beats per minute for secondary prevention (but at least 10 beats per minute below the clinical VT rate), 7 independent of whether this rate defines a VT or VF zone. For each manufacturer, Appendix B provides both a single, preferred rate threshold and a range of acceptable rate thresholds that are within guidelines. For primary prevention patients, preferred rate thresholds vary from 185 to 188 beats per minute; the range of acceptable thresholds extends from the preferred value to 200 beats per minute. For some ICDs, the Consensus Statement and its Appendix B permits more restrictive programming than tested in clinical trials, [8] [9] [10] [11] [12] [13] restricting therapy to faster rates. Table 1 summarizes patient demographics. Table I in  the Data Supplement shows device and implant data.  Table 2 shows programmed parameters. One column indicates whether rate threshold programming complied with the generic recommendations of the Consensus Statement (consensus recommendations) and by extension was within guidelines as determined by Appendix B. A second column indicates whether the rate threshold equaled Appendix B's preferred threshold for the specific manufacturer. Table 3 summarizes manufacturer-specific features that contributed to failure to deliver timely shocks.
RESULTS
Of the 8 patients who underwent implant testing, all had reliable sensing and detection of VF (maximum delay 1 s). Overall, 5 patients died of untreated VF, 4 patients required external defibrillation, and 1 patient was rescued by the ICD after aborted shocks. There was no evidence of a primary cause of cardiac arrest (eg, acute myocardial infarction, pulmonary embolus) in the 5 survivors or 3 patients who died after prolonged resuscitation. The flow chart in Figure 1 summarizes reasons for failure to deliver VF therapy.
Programming Consistent With Generic Consensus Recommendations (Cases 1 to 8)
In cases 1 to 8, rate thresholds complied with generic consensus recommendations; and SVT-VT discriminators complied with manufacturer preferences in Appendix B. 7
Premature VF Episode Termination (Cases 1 and 2)
In 2 cases, ICDs detected VF, but the device-defined VF episode terminated prematurely because of intermittent undersensing.
Case 1
A 66-year-old man with a primary prevention St. Jude Medical ICD had VF that was detected rapidly and defibrillated with a single shock. His physician found no change in clinical status and made no changes in programming or medication. Two months later, the patient had a witnessed, out-of-hospital cardiac arrest. Paramedics defibrillated him from VF 13 minutes after collapse. Spontaneous circulation returned, but he died of anoxic encephalopathy. Figure 2 shows that the stored electrogram (EGM) began with monomorphic VT slower than the programmed VT detection interval (315 ms, 190 beats per minute); this VT degenerated to VF. The ICD detected VF, but terminated the device-defined VF episode prematurely (Return to Sinus), aborting the shock because it undersensed VF EGMs. After this, the ICD neither detected VF nor stored EGMs before paramedics performed external defibrillation. The shock would have been delivered if the VT interval had been programmed to the clinically validated value of 333 ms (180 beats per minute) 12 rather than the manufacturer-preferred value (Consensus Statement Appendix B 7 ; Figure 2 and Figure I Analysis. Figure 3 shows that premature episode termination occurred for the initiating VT because antitachycardia pacing slowed the VT to 318 to 332 ms (180-189 beats per minute) below the rate threshold of 12 VT then degenerated to VF.
Analysis.
Three VF episodes terminated prematurely because of undersensing. It is likely that sensing enhancements designed to prevent T-wave oversensing 14 contributed to undersensing VF ( Figure II in the Data Supplement). 
VF Never Detected (Cases 3 to 7)
In 4 cases, the ICD did not detect the index episode of VF.
Case 3
A 62-year-old man with a primary prevention Medtronic cardiac resynchronization therapy ICD died suddenly and unexpectedly in his bedroom. A Lead Integrity Alert 15 was triggered by double-counted EGMs and transmitted to a remote monitoring network. Figure 4 and Figure EGMs from multiple nonsustained episodes over the next 46 minutes show that VT slowed to cycle length 290 to 330 ms and degenerated to polymorphic VT/ VF. Monomorphic VT would have been detected with a clinically validated VF interval of 330 ms (182 beats per minute) 8, 9 ; transmitted data are insufficient to determine whether detection would have occurred with the validated value of 320 ms (188 beats per minute). 10, 13 Case 4 A 79-year-old man with a primary prevention St. Jude Medical cardiac resynchronization therapy ICD had monomorphic VT with cycle length 260 to 280 ms in December 2016 that was detected and treated in the VT zone (240-300 ms). In January 2017, he had a witnessed cardiac arrest while sitting in a chair. Cardiopulmonary resuscitation was performed until paramedics arrived 9 minutes later and defibrillated him from polymorphic VT/VF to sinus rhythm ( Figure  IVA in the Data Supplement). He died despite pro- Analysis. Figure IVB in the Data Supplement shows the first of 3 similar episodes. Each persisted for an unknown duration with cycle length slower than the VT interval (300 ms) before accelerating into the VT zone. The subsequent stored VTs suggest that untreated VF may have begun with VT slower than the detection interval and that this VT degenerated to VF, which was undersensed.
Analysis.
Case 5
A 41-year-old man suffered an arrhythmic cardiac arrest on in-hospital telemetry, the night after elective implantation of a primary prevention Medtronic ICD. He had no metabolic abnormalities, and he received no antiarrhythmic drugs. After resuscitation, he required inotropic support and underwent heart transplantation 6 weeks later.
Analysis. Figure 5A shows that initial episode of lowfrequency VF did not fulfill the programmed detection criteria for either VF (18/24 intervals shorter than 300 ms) or VT (40 consecutive intervals, 16 300-319 ms). Double counting triggered the Lead Integrity Alert, 15 which extended the number of intervals to detect VF to 30 of 40. After external defibrillation, monomorphic VT occurred and degenerated to polymorphic VT with cycle length 310 to 350 ms ( Figure 
Case 6
An 87-year-old man with complete heart block and a primary prevention Medtronic cardiac resynchroniza-tion therapy ICD had a cardiac arrest while sleeping. His caregiver called 911. Paramedics found him in VF and defibrillated him to pulseless electric activity, but he did not regain spontaneous circulation. The ICD transmitted a Lead Integrity Alert. Figure VI in the Data Supplement show VF with undersensing that never fulfilled the detection criteria for VF (30/40 intervals shorter than 300 ms). Further, detection of VT did not occur despite a slow VT interval (400 ms) because Medtronic uses consecutive interval counting in the VT zone. Undersensing or entrance block caused occasional device-measured intervals slower than the VT interval, which repeatedly reset the VT count to 0 ( Figure VI in the Data Supplement).
Analysis. The transmitted EGMs in
Case 7
A 75-year-old man with long-standing atrial fibrillation had an ICD implanted in 1994 for out-of-hospital VF and upgraded in 2011 to a Biotronik cardiac resynchronization therapy ICD. In 2015, his electrophysiologist increased the VT detection interval to 400 ms after the patient had suspected arrhythmic syncope. One month later, he had a witnessed cardiac arrest followed by immediate cardiopulmonary resuscitation. Paramedics found him in VF and defibrillated him to pulseless electric activity. He died after a prolonged resuscitation including repetitive sequences of VF.
Analysis. Relevant ICD parameters include detection intervals consistent with recommended secondary prevention programming (VT1: 400 ms, VT2: 330 ms, VF: 260 ms) and nominal values of single-chamber SVT-VT discriminators: Onset at 20% and Stability at 24 ms. 7, 17 Stored EGMs at the time of collapse recorded monomorphic VT at cycle length 375 to 344 ms in the VT zone that did not fulfill the Onset criterion and was thus classified as SVT ( Figure 6A ). The stored EGM in Figure 6B was recorded 13 minutes later and shows VF. Because of intermittent undersensing, the calculated ventricular cycle length (276 ms) was in the VT2 zone, so the Stability algorithm was applied and determined that the rhythm was irregular. Thus, the ICD classified VF as SVT and withheld therapy ( Figure 6 ).
Postshock Undersensing (Case 8)
Case 8
A 67-year-old man underwent Boston Scientific ICD implantation with an integrated bipolar lead after out-of-hospital VF. One month later, he suffered a witnessed cardiac arrest. Paramedics arrived 12 minutes later and defibrillated VF after a long resuscitation. With prolonged hospitalization, the patient recovered completely and underwent VT ablation.
Analysis. Figure VII in the Data Supplement shows monomorphic VT that degenerated to VF, which was detected and defibrillated to sinus rhythm. This initiated a repetitive sequence of recurrent VF followed by successful defibrillation. However, the amplitude of the sensed EGMs decreased progressively in successive postshock recurrences of VF until they were undersensed consistently and VF remained undetected ( Figure VII in the Data Supplement).
Deviation From Consensus Programming (Cases 9 to 10)
In case 9, the VT interval was set to 300 ms after apparently successful ablation of slower VT; the patient presented with VT slower than 300 ms and subsequent undersensed VF ( Figure 
Completeness of the Data Set
No patient who met the study criteria was knowingly excluded. We reviewed all cardiac arrests and other deaths in ICD patients during the study period at the 2 institutions that tracked these data. These institutions contributed 8 of 10 cases, including 3 of the 4 cardiac arrest cases and all 5 fatal cases. There were no other resuscitated cardiac arrests during the study period.
Of 47 total decedents during the study period, 9 died suddenly. In addition to the 5 study patients who died, 2 patients died of pulseless electric activity, 1 patient with a fractured defibrillation lead died of VF that was detected but not defibrillated, and 1 patient died suddenly without postmortem ICD interrogation (Table II in  the Data Supplement) . Thus, failure to detect VF despite recommended programming was responsible for 5 of 8 adjudicated sudden deaths (62%), 56% of total sudden deaths, and 11% of all deaths in ICD patients.
DISCUSSION
We present a series of contemporary ICD patients who did not receive timely VF shocks. Our principal finding is that, in most patients, ICD programming deviated from values validated in manufacturer-specific, clinical trials, [8] [9] [10] [11] [12] [13] which form the evidence base for the Consensus Statement, 7 but they complied with more restrictive, generic recommendations of the Consensus Statement. Failure to detect VF despite generically recommended programming was the most common cause of sudden death at the 2 centers that tracked these data. These data suggest that differences in sensing and detection methods among manufacturers may limit the applicability of generic programming recommendations.
Prior Studies: Programming Sensing and Detection of VT/VF
In the last decade, randomized clinical trials 9-12 and prospective observational studies 8, 13 in primary prevention patients found that faster rate thresholds of 180 to 200 beats per minute and longer durations of at least 6 to 12 s reduce unnecessary shocks [8] [9] [10] [11] [12] [13] and may reduce mortality. 18 Programmed parameters were tightly controlled within each study using ICDs from a single manufacturer, but varied among studies using different manufacturers' ICDs. Importantly, studies report no deaths from untreated VT/VF. Programmed, slowest rate thresholds were 182 to 188 beats per minute for Medtronic ICDs [8] [9] [10] 13 Figure IIB in the Data Supplement shows sequential VF episodes 1 to 3 in which VF detection criteria were met, but shocks were aborted because of undersensing that caused premature episode termination. Figure 3B The Consensus Statement 7 relied on this evidence to develop generic programming recommendations including a range of reasonable heart rate cutoffs that are inclusive of those proven in good-quality trials. Its online Appendix B provides manufacturer-preferred examples intended to best approximate the recommended behaviors for each available ICD model.
Present Study
In contrast to clinical trials [8] [9] [10] [11] [12] [13] in which no patient died from untreated VT/VF with manufacturer-specific programming, we report patients with adverse outcomes. Overall, failure of VF to satisfy programmed detection criteria was critical in 9 of our 10 patients (90%, all but patient 8). Patients 1 to 8 had programming consistent with generic, Consensus Statement recommendations. However, in patients 1 to 6, programming was inconsistent both with manufacturer-specific, clinical trials and manufacturer-preferred values (online Appendix B). In patient 7, programming complied with manufacturer-preferred values, but these values had not been validated in a peer-reviewed, clinical study. Programming a detection rate validated clinically for the manufacturer's ICD would have resulted in prompt shocks for at least 4 other patients (1-3, 10); of these, patient 1 would not have received prompt shocks with manufacturer-preferred programming.
Our cases illustrate how variability of VF within patients necessitates a safety margin for detection: all 8 ICDs tested at implant detected VF reliably with the settings that failed to detect the index VF; 2 detected spontaneous VF or rapid VT before the index VF (cases 1, 4), and 1 detected VF after external defibrillation (case 5). Overall, failure of VF therapy accounted for 11% of deaths in ICD patients at institutions that tracked these data. In a postmortem series, Tseng et al 20 reported that similar failures accounted for 6% of deaths in ICD patients.
Interaction of Manufacturer-Specific Features With Generic Programming
Counting Methods, Detection Duration, and SVT Discriminators
Manufacturers use different methods to count ventricular intervals that satisfy rate criteria. 14, 16, 17, 21 Each method tolerates slow intervals in the VF zone. However, Boston Scientific tolerates more slow intervals (40%) than Medtronic (25%) or Biotronik (33%); yet only Boston Scientific ICDs have been tested with a slowest detection rate of 200 beats per minute and only for durations less than about 5 s. 11 Patient 3 was programmed to 200 beats per minute using Medtronic counting for a longer duration (30/40 intervals) that was tested for slower rates of 182 10, 13 or 188 beats per minute. 8, 9 Therapy would have been delivered with a threshold of 182 beats per minute. Without a monitoring zone, we cannot determine whether therapy would have occurred with a threshold of 188 beats per minute. Similarly, we cannot determine whether validated programming would have resulted in prompt therapy in patients 4 and 5.
In addition, counting methods for the VT zone vary among manufacturers. Medtronic ICDs count consecutive intervals. 16 During VF in patient 6, the VT count was repeatedly reset to 0 by intermittent, device-measured intervals slower than the VT interval, which occurred because of undersensing or entrance block. Biotronik ICDs use up/down counting. 17 In patient 7, VF with undersensing had a measured rate of 217 beats per minute (276 ms) in the VT2 zone. This constituted a problem because unvalidated, manufacturer-preferred programming of the Stability discriminator ≤231 beats per minute (260 ms) prevented detection of VF; Stability discriminators are of little value >200 beats per minute.
Episode Termination Rules
ICD-defined VT/VF episodes continue until the rhythm is classified as normal (sinus) based on (slow) rate and duration. Therapy is not delivered if the episode terminates prematurely. St. Jude Medical ICDs have the most sensitive episode termination rule. 14 Cases 1 and 2 show how it interacts with fast detection rates and occasional undersensing to withhold therapy after VF has been detected.
Enhancements to Minimize T-Wave Oversensing
St. Jude Medical sensing enhancements Decay Delay and Threshold Start 14 ( Figure X in the Data Supplement) increase ventricular blanking and have been associated with VF undersensing. 1, 20 The low-frequency attenuation filter may reduce the amplitude of VF EGMs more than the amplitude of sinus-rhythm EGMs because VF EGMs have lower frequency content than sinus-rhythm EGMs. 22 In the St. Jude Medical PROVIDE trial of strategic programming (Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication to Prolong Time to First Shock), 12 the detection rate was 180 beats per minute; use of Decay Delay and Threshold Start were not controlled; and most ICDs predated the low-frequency attenuation filter. Thus, the interaction of these features with a detection rate of 200 beats per minute is untested.
Additional Factors
Patients 8 to 10 illustrate known mechanisms of withholding VF therapy. In patient 8, postshock undersensing of VF occurred after repetitive shocks through an integrated bipolar lead. 23 Patient 9 was considered cured of VT after ablation, so his ICD was set to primary prevention parameters; in studies of VT ablation, detection rates have not been reprogrammed after VT was rendered noninducible. Case 10 emphasizes the importance of reprogramming the detection rate when antiarrhythmic drugs are added. 7
Role of Preceding Monomorphic VT in Withholding VF Therapy
Untreated monomorphic VT initiated polymorphic VT/VF in 7 of the 8 patients in whom we could determine the The implantable cardioverter-defibrillator (ICD) did not record the onset of ventricular fibrillation (VF). It recorded the first device-defined, nonsustained episode (episode 1) at 03:48. A, Nonsustained episode 6 at 03:49 is the last episode recorded before the first external defibrillation. VF EGMs have a low-frequency content and do not fulfill the programmed detection criteria for either VF (18/24 intervals shorter than 300 ms) or ventricular tachycardia (VT; 40 consecutive intervals shorter than 320 ms). Intervals in the VT zone do not contribute to detection because consecutive interval counting causes each interval in the sinus zone (320 ms or greater) to reset the VT count to 0. Undetected recurrence of undetected monomorphic and polymorphic VT is shown in Figure VB in the Data Supplement. C, VF episode 9 at 03:55. Three continuous panels show polymorphic VT with cycle length 270 to 430 ms that does not satisfy interval/duration criteria for detection and requires a second external shock (Panel 2, up arrow). If the VF interval had been programmed to the clinically validated values of 320 or 330 ms, this polymorphic VT would have satisfied the programmed 18/24 intervals for detection of VF (end of dotted arrow in Panels 1 and 2). However, the Lead Integrity Alert 15 was activated incorrectly during Episode 5 when both oversensing criteria were fulfilled. This alert increased the number of intervals for VF detection to 30/40 during Episode 6 and subsequent episodes. After the shock, VT recurred following the second paced beat and immediately accelerated to VF. The frequency content of EGMs was higher during this VF than during the first VF or the polymorphic VT above. The ICD detected VF rapidly and defibrillated it with a single shock ( Figure VC initiating rhythm. In at least 4 of these patients, clinically validated, manufacturer-specific programming would have treated VT before it degenerated to VF. Further, VF that arises from prolonged VT may be difficult to detect or treat. Although low-frequency VF has been considered an agonal rhythm, metabolic changes during VT may produce de novo, low-frequency VF (patients 3, 7, and 9) because of local conduction block or hyperkalemia, resulting in long device-detected intervals because of undersensing or entrance block. 6 Patient 5's first recorded rhythm was low-frequency VF, but recurrence of high-frequency VF promptly after the first defibrillation indicates that the presenting VF was not an agonal rhythm. In addition, prolonged VT may cause metabolic changes that facilitate early postshock recurrence of VT/ VF (eg, catecholamine release, patients 4, 5, 7-9).
Clinical Implications
VF detection algorithms must be robust against devicedetected intervals slower than the rate threshold to compensate for undersensing, entrance block, or detection restrictions applied in VT zones. Both fast detection rates and enhancements that facilitate undersensing increase the fraction of such device-detected, slow intervals. When devices measure slow intervals, strict counting methods and the Stability discriminator reduce sensitivity for detecting VF in VT zones; sensitive episode termination rules reduce the likelihood that VF therapy will be delivered once VF is detected; and long detection times enhance both effects. Finally, fast detection rates may increase the likelihood that VT will not be detected until it degenerates to low-frequency VF, which may be difficult to detect.
Ideally, programming should deliver all life-saving ICD therapy but no unnecessary therapy. Practically, the programmer's dilemma is to balance the risks of failure to treat VF with the risks of inappropriate therapies. Although evidence-based, manufacturer-specific programming may withhold necessary therapy, the absence of deaths from untreated VF in the 6414 patients in strategic programming groups of clinical trials 8-13 places a low, upper bound on the likelihood of such events.
Our cases illustrate how complex and unanticipated interactions between manufacturer-specific features and generic rate thresholds can withhold therapy for VF. Programming manufacturer-preferred values enumerated in Appendix B might have prevented some, but not all, treatment failures. No patient with manufacturer-specific, programming validated in a clinical trial failed to receive an initial, timely shock for VF. Thus indirectly, our study supports the recommendation of the Consensus Statement 7 (Section 23) encouraging programming ICDs to manufacturer-specific therapies of proven benefit; we recommend such programming even if Appendix B permits programming to other val-ues. Our study identifies risk associated with programming recommendations extrapolated from evidence obtained using another manufacturer's ICDs with different sensing and detection features; however, we cannot provide alternative recommendations and do not advocate abandonment of any recommendations of the Consensus Statement.
Limitations
We did not compare adverse outcomes using evidence-based manufacturer-specific programming and more restrictive, generic programming. Although such generic programming accounted for 62% of adjudicated sudden deaths in ICD patients at institutions that tracked outcomes, our series of cases is too small for definitive conclusions.
Even if manufacturer-specific, evidence-based programming is available for an ICD, programming more restrictive values permitted by the Consensus Statement Appendix B may further reduce unnecessary therapies and thus further reduce morbidity beyond the reduction provided by evidence-based programming. However, the low rate of unnecessary therapy in evidencebased clinical trials places a low upper bound on the incremental benefit of such programming.
Conclusions
Given the rarity of failure to treat VF with evidencebased, manufacturer-specific programming, failures of generic programming constitute a readily preventable cause of sudden death. More data are needed to assess both the benefits and risks of applying generic programming recommendations to specific ICDs in which these recommendations have not been validated clinically. 
AFFILIATIONS
ACKNOWLEDGMENTS
We are grateful to Sylvain Ploux, MD, for his critical review of this article.
DISCLOSURES
Dr Abedin is a consultant to St. Jude Medical. Dr Swerdlow is a consultant to Medtronic and has received speaking hono-
